Updated 2/23/26
Stepan Company, since its founding back in 1932, has stayed the course—quietly supplying chemicals that go into everything from shampoo and cleaning products to building insulation and construction materials. While it might seem like a behind-the-scenes player, Stepan plays an important role in industries that touch everyday life.
Over the years, it has earned a solid reputation for dependability, especially among long-term investors who value dividends and financial discipline. Despite persistent challenges on the earnings front, the company continues to reward shareholders and maintain its impressive dividend track record.
Recent Events
The past year has remained difficult for Stepan shareholders. Shares are currently trading at $53.53, sitting near the lower end of their 52-week range of $41.82 to $68.00—representing a significant discount from recent highs. The pressure continues to stem from weaker demand across its surfactant and polymer businesses, alongside a broader softness in industrial and construction activity.
Revenue has held around $2.30 billion, but profitability remains strained. Net income has slipped to $45.2 million, and the profit margin has compressed to just 1.96%. Return on equity now stands at 3.67%, and return on assets is 1.96%—both well below levels investors have historically associated with Stepan. EPS for the trailing period comes in at $1.98, which keeps the payout ratio elevated at approximately 77.78%.
Despite the continued earnings softness, management pushed through another modest dividend increase in late 2025, raising the quarterly payment to $0.395 per share—a signal that the board remains committed to preserving its extraordinary streak of consecutive annual increases.
Key Dividend Metrics
💰 Forward Dividend Yield: 2.95%
📈 5-Year Average Yield: 1.39%
📅 Consecutive Years of Dividend Increases: 57
📊 Payout Ratio: 77.78%
💵 Annual Dividend: $1.58
🔁 Dividend Growth (5-Year Avg): ~6%
📉 Share Price vs. 52-Week High: -21.3%
📊 Beta: 1.03
Dividend Overview
Stepan’s dividend story remains one of quiet consistency, even as the financial backdrop has grown more challenging. The most recent quarterly payment was $0.395 per share, bringing the annualized dividend to $1.58. At the current price of $53.53, that translates to a forward yield of approximately 2.95%—meaningfully above the company’s five-year average yield of around 1.39%, largely a function of the depressed share price rather than any reduction in the payout.
The payout ratio has climbed to 77.78% based on trailing EPS of $1.98, which is higher than where Stepan has historically operated and warrants close monitoring. That said, operating cash flow of $156 million over the trailing twelve months provides a more comfortable cushion than the earnings-based ratio alone would suggest, as the dividend obligation on an annualized basis remains well within reach of the company’s cash generation.
Dividend Growth and Safety
This is where Stepan continues to distinguish itself. The company has now increased its dividend for 57 consecutive years, firmly cementing its status as a Dividend King. The November 2025 increase—from $0.385 to $0.395 per quarter—marked the latest step in a streak that spans more than five decades of uninterrupted payout growth.
Dividend growth has moderated compared to the 9% five-year average cited in prior periods, with recent annual increases running closer to 2-3% as the company navigates tighter margins. While that’s a slower pace, it reflects management’s intent to keep raising the dividend in a disciplined way rather than stretch the balance sheet. The board has consistently prioritized the streak, even through prior downturns.
Free cash flow of $27.7 million over the trailing period is the one area that deserves attention. It is thin relative to total dividend obligations, meaning Stepan is relying on its broader operating cash flow base—$156 million—and balance sheet capacity to sustain the payout through the current trough. If margins don’t recover in 2026, dividend growth could slow further, though an outright cut seems unlikely given the company’s history and stated priorities.
Analyst Ratings
Formal analyst coverage updates are limited in the most recent data window, but the financial profile tells a clear story. With trailing EPS at $1.98 and the stock trading at $53.53, the trailing P/E stands at 27.04—elevated given the current profitability environment. Price-to-book has dipped below 1.0 at 0.97, with book value per share at $55.12, meaning the stock is trading at a modest discount to its tangible net asset value. That is a relatively rare occurrence for a specialty chemical Dividend King and reflects the degree to which the market has repriced the shares.
The prior consensus price target from covering analysts was $90, which now appears to have been set during a more optimistic period for margins and volumes. Given where earnings have settled, a more conservative near-term target in the $60–$70 range would be consistent with a modest recovery scenario. Any meaningful re-rating to the upside will likely require visible improvement in operating margins and a resumption of volume growth across both the surfactants and polymers segments.
Short interest of 344,500 shares is relatively modest, suggesting the market is not aggressively positioned against the stock. That, combined with the below-book valuation, may offer some downside support at current levels.
Earning Report Summary
Profitability Under Pressure Across the Board
Stepan’s most recent financial results reflect the ongoing margin squeeze that has defined the past several quarters. Net income of $45.2 million on $2.30 billion in revenue produces a profit margin of just 1.96%, which is historically low for the company. EPS came in at $1.98 for the trailing period, a figure that reflects both the volume softness and the cost pressures that have weighed on results since late 2023.
Operating cash flow of $156 million demonstrates that the underlying business continues to generate cash, even if reported earnings are suppressed by elevated expenses, including costs associated with the Pasadena alkoxylation facility ramp-up and other one-time charges. Free cash flow, however, has narrowed considerably to $27.7 million, reflecting higher capital expenditure as the company invests in capacity expansion.
Surfactants and Polymers
Stepan’s surfactants segment continues to be the more resilient of the two major business lines, with demand from consumer product manufacturers providing a relatively stable base. The polymers segment has remained the softer spot, facing continued pricing pressure and volume headwinds tied to slower construction activity and customer destocking. The interplay between these two segments has defined much of the earnings volatility over the past year, with polymers dragging on consolidated margins even as surfactants hold relatively steady.
Looking Ahead
The key catalyst to watch in 2026 is the contribution from the new Pasadena, Texas alkoxylation facility, which was expected to come online in the first quarter of 2025. Management has pointed to this asset as a meaningful driver of improved product mix and margin recovery across all segments. If the plant ramps as planned, it could provide a visible lift to both operating income and free cash flow as 2026 progresses—which would also ease concerns about the elevated payout ratio.
Financial Health and Stability
While profitability remains subdued, Stepan’s overall financial structure is intact. Return on assets sits at 1.96% and return on equity at 3.67%—both well below long-term norms, but consistent with a company navigating a cyclical trough rather than a structural deterioration. The balance sheet retains a manageable debt load, and the current ratio suggests adequate near-term liquidity.
Book value per share of $55.12 is particularly notable in the current context. With the stock trading at $53.53, Stepan is priced at a slight discount to book—a price-to-book ratio of 0.97. For a specialty chemical company with 57 years of consecutive dividend increases and an established market position, that valuation is historically unusual and may attract value-oriented income investors. It also provides a measure of fundamental support to the share price at current levels.
Market capitalization stands at approximately $1.21 billion, which keeps Stepan in small-cap territory and means institutional coverage remains relatively limited compared to larger chemical peers.
Valuation and Stock Performance
At $53.53, Stepan’s valuation reflects the market’s skepticism about near-term earnings recovery. The trailing P/E of 27.04 appears high in isolation, but it is almost entirely a function of compressed earnings rather than an elevated multiple on normalized profitability. If margins recover toward historical levels—and management’s guidance on the Pasadena facility suggests a path in that direction—the implied forward multiple on a normalized earnings base would look considerably more reasonable.
The price-to-book ratio of 0.97 is the more compelling valuation data point. Trading below book value is not something that occurs frequently for companies with Stepan’s dividend lineage, and it suggests the market has priced in a fairly pessimistic scenario. For long-term income investors, the combination of a sub-book valuation and a yield approaching 3% represents a more attractive entry point than the stock has offered in recent memory.
The stock’s beta has ticked up to 1.03, slightly above the market, reflecting increased sensitivity to broader industrial and chemical sector moves compared to its historically low-volatility profile. That’s worth keeping in mind for investors who have traditionally viewed SCL as a defensive holding.
Risks and Considerations
The risks facing Stepan today are real and deserve clear-eyed acknowledgment. Margin compression remains the most immediate concern. With the profit margin at just 1.96% and the payout ratio at 77.78% of earnings, there is limited cushion if conditions deteriorate further before the Pasadena facility delivers on its expected earnings contribution. A meaningful miss on that ramp-up timeline would put additional pressure on free cash flow and could test the board’s commitment to dividend growth.
Volume trends in the polymers segment remain a second-order risk. Customers working through excess inventory and a slower construction backdrop have muted demand, and there is no guarantee that destocking cycles resolve quickly. Pricing power in certain product lines has also been challenged, limiting Stepan’s ability to offset cost increases through price.
The rising payout ratio—now approaching 78% of earnings—deserves continued monitoring. While operating cash flow provides a broader cushion, the trend is moving in the wrong direction, and another year of flat or declining earnings would narrow the margin of safety further. Stepan’s long dividend history makes an outright cut extremely unlikely in the near term, but growth could slow to token increases if profitability doesn’t improve.
Finally, with a beta now at 1.03 and a market cap just above $1.2 billion, SCL is more exposed to macro volatility and sector sentiment shifts than its defensive reputation might imply. A prolonged slowdown in industrial activity, construction, or consumer product demand would weigh on both segments simultaneously.
Final Thoughts
Stepan isn’t going to dazzle anyone with explosive earnings growth or dramatic margin expansion in the near term. What it continues to offer is a 57-year dividend growth streak, a sub-book valuation that is historically rare for this company, and a yield approaching 3% at current prices—all characteristics that speak directly to the income investor’s checklist.
The path to re-rating requires margin recovery, and the Pasadena facility represents the most tangible near-term catalyst for that to happen. Until that contribution becomes visible in the quarterly numbers, the stock is likely to remain range-bound and under-appreciated by the broader market.
For investors with a long time horizon and a focus on dividend longevity over short-term earnings momentum, Stepan at $53.53—trading below book value with a growing payout and 57 years of consecutive increases behind it—remains a name worth owning. It’s not the most exciting position in a dividend portfolio, but durability rarely is.